Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; A randomized controlled trial

British Journal of Dermatology

Volumn 157, Issue 2, 2007, Pages 378-381

  Spergel, J M ^a,f   Boguniewicz, M ^b   Paller, A S ^c   Hebert, A A ^d   Gallagher, P R ^a   McCormick, C ^e   Parneix Spake, A ^e   Hultsch, T ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Atopic dermatitis; Combination therapy; Fluticasone; Pimecrolimus

Indexed keywords

FLUTICASONE; PIMECROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; OTITIS MEDIA; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 34447517420     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08001.x     Document Type: Article

References (14)

1. Furue M, Terao H, Rikihisa W et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 2003 148 : 128 33.
2. Boguniewicz M, Eichenfield LF, Hultsch T. Current management of atopic dermatitis and interruption of the atopic march. J Allergy Clin Immunol 2003 112 : S140 50.
3. Lee MJ, Pyszczynski N, Jusko WJ. Combined inhibition effects of tacrolimus and methylprednisolone on in vitro human lymphocyte proliferation. Immunopharmacol Immunotoxicol 1995 17 : 335 45.
4. Spergel J, Hultsch T. Pimecrolimus cream 1% and fluticasone propionate cream 0·05% versus fluticasone propionate cream 0·05% for the treatment of flares of atopic dermatitis. Poster Presented at the 28th Annual Hawaii Dermatology Seminar, 2004.
5. Eichenfield LF, Hanifin JM, Luger TA et al. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol 2003 49 : 1088 95.
6. Hanifin J, Thurston M, Omoto M et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001 10 : 11 18.
7. Hebert AA, Koo JY, Fowler AJ et al. Desoximetasone 0·25% and tacrolimus 0·1% versus tacrolimus 0·1% alone in the treatment of atopic dermatitis. Cutis 2006 78 : 357 63.
8. Torok HM, Maas-Irslinger R, Slayton RM. Clocortolone pivalate cream 0·1% used concomitantly with tacrolimus ointment 0·1% in atopic dermatitis. Cutis 2003 72 : 161 6.
9. Gupta A. The use of combination of prednicarbate/tacrolimus versus tacrolimus alone to treat atopic dermatitis in children (abstract). J Am Acad Dermatol 2005 52 : 74.
10. Blum R, Berman B, Koo J et al. An evaluation of the concurrent use of fluticasone cream and tacrolimus ointment in the treatment of atopic dermatitis. Poster Presented at the American Academy of Dermatology Summer Meeting. New York, NY, U.S.A., 2003.
11. Meurer M, Folster-Holst R, Wozel G et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002 205 : 271 7.
12. Nakahara T, Koga T, Fukagawa S et al. Intermittent topical corticosteroid/tacrolimus sequential therapy improves lichenification and chronic papules more efficiently than intermittent topical corticosteroid/ emollient sequential therapy in patients with atopic dermatitis. J Dermatol 2004 31 : 524 8.
13. Hauk PJ, Leung DY. Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis? J Allergy Clin Immunol 2001 107 : 391 2.
14. Caproni M, Torchia D, Antiga E et al. The effects of tacrolimus ointment on regulatory T lymphocytes in atopic dermatitis. J Clin Immunol 2006 26 : 370 5.